The Genome Technologies Program uses cancer genome sequencing and other high-throughput techniques to identify genes critical to the development of cancer and anomalies in the genomic profile of tumours. Genetic mutations involved in pancreatic cancer are being mapped as part of the program’s role in the International Cancer Genome Consortium. The Program also fosters a relationship with The Broad Institute of Harvard and MIT to collaborate on RNAi technology.
Lead Principal Investigator
Dr. John McPherson